CONTRACEPTION: A PRIMER FOR HEALTHCARE PROFESSIONALS
Faculty:
L. Austin Fredrickson, MD, FACP
L. Austin Fredrickson is an Associate Professor of Internal Medicine at Northeast Ohio Medical University, where he serves as core faculty and teaches diagnostics, therapeutics, clinical skills, and health humanities. He is board-certified in general internal medicine and practices rural primary care. 
Anna Shurtleff Smith, MPH, BSN-RN
Anna Shurtleff Smith is a graduate of the University of North Texas Health Science Center, School of Public Health, with a community health focus, and Texas Tech University School of Nursing. She has clinical experience in both inpatient and outpatient settings. Anna is passionate about patient education, health literacy, and health communications.
Liz Fredrickson, PharmD, BCPS
Liz Fredrickson, PharmD, BCPS, is an Associate Professor of Pharmacy Practice and Pharmaceutical Sciences at the Northeast Ohio Medical University (NEOMED) College of Pharmacy, where she is course director of the Parenteral Products and Basic Pharmaceutics Lab courses.
Pamela Sardo, PharmD, BS
Pamela Sardo, PharmD, BS, is a freelance medical writer and licensed pharmacist. She is the founder and principal at Sardo Solutions in Texas. Pam received her BS from the University of Connecticut and her PharmD from the University of Rhode Island. Pam’s career spans many years in retail, clinics, hospitals, long-term care, Veterans Affairs, and managed health care responsibilities across a broad range of therapeutic classes and disease states.
Abstract
Contraception is the use of methods or techniques to prevent pregnancy. Nearly all women who have ever had sexual intercourse have used some form of contraception, and 88% of women who seek pregnancy prevention report using contraception at any given time. Patients seeking contraception should be informed and supported through a shared decision-making model with their healthcare providers. Contraceptive counseling can be implemented to determine a patient’s preferences, values, and insights and ensure reproductive goals are being met. Additionally, providing evidence-based education on the use, efficacy, and side effects ensures patients are well-informed and utilize contraception safely and effectively. This course will detail currently available nonhormonal and hormonal contraceptive options, with a review of appropriate use, failure rates, pertinent side effects, and contraindications. This course will also discuss strategies for selecting a contraceptive method and counseling patients on the selection and use of contraceptives.
Accreditation Statements
In support of improving patient care, RxCe.com LLC is jointly accredited by the Accreditation CouncilTM for Continuing Medical Education (ACCME®), the Accreditation Council for Pharmacy Education (ACPE®), and the American Nurses Credentialing Center (ANCC®), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 3 Interprofessional Continuing Education (IPCE) credits for learning and change.
Joint Universal Activity Number: The Joint Accreditation Universal Activity Numbers assigned to this activity are as follows:
Pharmacists: JA4008424-0000-26-053-H01-P
Pharmacy Technicians: JA4008424-0000-26-053-H01-T
Credits: 3 contact hour(s) (0.3 CEU(s)) of continuing education credit.
Credit Types:
IPCE Credits - 3 Credits
AAPA Category 1 Credit™️ - 3 Credits
AMA PRA Category 1 Credit™️ - 3 Credits
Pharmacy - 3 Credits
Type of Activity: Application
Media: Computer-Based Training (i.e., online courses)
Estimated time to complete activity: 3 contact hour(s) (0.3 CEU(s)), including Course Test and course evaluation.
Release Date: April 24, 2026 Expiration Date: April 24, 2029
Target Audience: This educational activity is for Physicians, Physician Assistants, Pharmacists, and Pharmacy Technicians
How to Earn Credit: From April 24, 2026, through April 24, 2029, participants must:
Read the “learning objectives” and “author and planning team disclosures;”
Take the “Educational Activity Pre-Test;”
Study the section entitled “Educational Activity;” and
Complete the Educational Activity Post-Test and Activity Evaluation. The Educational Activity Post-Test will be graded automatically. Following successful completion of the Educational Activity Post-Test with a score of 70% or higher, a statement of participation will be made available immediately. (No partial credit will be given.)
CME Credit: Credit for this course will be uploaded to CPE Monitor® for pharmacists. Physicians may receive AMA PRA Category 1 Credit™️ and use these credits toward Maintenance of Certification (MOC) requirements. Physician Assistants may earn AAPA Category 1 CME credit, reportable through PA Portfolio. All learners shall verify their individual licensing board’s specific requirements and eligibility criteria.
Statement of Need
Healthcare professionals require updated knowledge of contraceptive methods due to the ongoing high unintended pregnancy rates of up to 45% in the United States. There is widespread use of contraceptive methods among women seeking pregnancy prevention. Variability in efficacy, side effects, contraindications, and patient-specific factors challenges the healthcare system despite a multitude of contraceptive options. Gaps in shared decision-making and counseling remain in vulnerable groups, like adolescents and post-partum women. This activity aims to address these gaps by differentiating among contraceptive methods, identifying counseling considerations, recalling side effects, and engaging in interprofessional collaboration to enhance patient outcomes.
Learning Objectives: Upon completion of this educational activity, participants should be able to:
Compare and contrast contraceptive methods
Differentiate the risk-benefit profile of contraceptives
Identify important considerations when selecting and counseling patients on contraceptives
Disclosures
The following individuals were involved in planning, developing, and/or authoring this activity: L. Austin Fredrickson, MD, FACP; Liz Fredrickson, PharmD, BCPS; Anna Shurtleff Smith, MPH, BSN-RN; and Pamela Sardo, PharmD, BS. None of the individuals involved in developing this activity has a conflict of interest or financial relationships related to the subject matter. There are no financial relationships or commercial or financial support relevant to this activity to report or disclose by RxCe.com or any of the individuals involved in the development of this activity.
© RxCe.com LLC 2026: All rights reserved. No reproduction of all or part of any content herein is allowed without the prior, written permission of RxCe.com LLC.
Educational Activity Pre-Test
Which of the following is the most appropriate contraceptive for a 40-year-old woman who smokes 20 cigarettes a day?
Ethinyl estradiol and norelgestromin
Copper-releasing IUD
Progestin and estrogen-releasing vaginal ring
Oral norethindrone acetate and ethinyl estradiol
Which of the following is associated with an increased risk of thromboembolism?
Ethinyl Estradiol
Levonorgestrel
Drospirenone
Norethindrone
The risk of decreased bone mineral density is associated with which of the following types of contraception?
Combined hormonal contraceptives
Hormonal intrauterine devices
Injectable progestins (e.g., depot-medroxyprogesterone acetate)
Progestin-only formulations
Educational Activity
Contraception: A Primer for Healthcare Professionals
Introduction
Contraception is the use of methods or techniques to prevent pregnancy. Patients seeking contraception should be informed and supported through a shared decision-making model with their healthcare providers. To ensure reproductive goals are met, the choice of contraceptive method should depend not only on a patient’s medical history but also on their preferences, values, and insights. Additionally, providing evidence-based education on the appropriate use, efficacy, and side effects associated with contraceptives ensures patients are well-informed and utilize contraception safely and effectively. This course will detail currently available nonhormonal and hormonal contraceptive options, with a review of administration, failure rates, pertinent side effects, and contraindications. This course will also discuss strategies for selecting a contraceptive method and counseling patients on the selection and use of contraceptives.
Contraception: Prevalence and Options
Nearly all women who have ever had sexual intercourse have used some form of contraception, and 88% of women who seek pregnancy prevention report using contraception at any given time.1 In addition, rates of pregnancy are as high as 45% in the United States (U.S.), and thus understanding available contraception options helps healthcare professionals inform patients and promote reproductive autonomy.2 This is best accomplished through shared decision-making and evidence-based education on the appropriate and safe use, efficacy, and side effects associated with contraceptives.3
Contraceptive methods prevent pregnancy through many mechanisms, including barrier methods, by preventing ovulation, or by creating a hostile uterine environment that prevents a fertilized ovum from successfully implanting.4 They can be broadly classified as hormonal versus non-hormonal methods or long-acting versus short-acting methods.1 Despite commonalities in mechanisms of action, contraceptives can differ greatly in their efficacy, side effect profiles, and contraindications. Important considerations that influence the choice of contraception include failure rate, safety, and return to fertility.5
Contraceptive failure is an important consideration when counseling patients and is a means by which to assess the effectiveness of a contraceptive method.5 Failure is defined as the percent of women who will have an unintended pregnancy occur during the first year of contraceptive use and can be considered either perfect-use failure or typical-use (user) failure.4,5 Perfect-use failure occurs when the patient used the contraceptive properly, but the pregnancy still occurred.4 Typical-use failure accounts for both perfect-use failure and failure subsequent to a patient not following directions or staying adherent to therapy.4 Failure rates are generally reported as typical-use failures, given that these include both perfect-use and user-failure rates.4 Health care providers can assist women with preventing unintended pregnancies by providing education on the correct use of contraceptives, thereby lowering typical-use failure rates. Table 1 details failure rates associated with perfect use and typical use of various contraceptive methods.5
Table 1
Failure Rates of Birth Control Methods5
| Method | Perfect Use (%) | Typical Use (%) |
| Combined hormonal contraceptives | 1 | 7-9 |
| Progestin-only pills | 1 | 7 |
| Progestin injection (DMPA) | <1 | 4 |
| Implant | <1 | <1 |
| Intrauterine device (IUD) | <1 | <1 |
Selecting a Contraception Option
The World Health Organization provides a medical eligibility criterion (MEC) for contraceptive use, which is used all over the world.6 The included chart provides a quick overview of which contraceptives are indicated for various conditions.6 In the U.S., the Centers for Disease Control and Prevention (CDC) published its 2024 MEC for contraceptive use.7
Although all women’s contraceptive use is essential, there are two populations that are most vulnerable to poor outcomes if they become pregnant. First, adolescents face the life-altering impact that having an infant will have on them.8 Second, postpartum women are at risk to both the fetus and the mother if pregnancies are too close together.9
Nurses' role in contraceptive care has begun to increase, including in 2023, when Georgia registered nurses were allowed to administer Nexplanon® and other contraceptive implants.10 As of September 1, 2023, registered nurses can “dispense contraceptives and drugs for sexually transmitted infections care in outpatient settings” in 16 states.11 In addition, nurses will now be asked by patients and their community to provide insight into the over-the-counter usage of Norgestrel. Nurses are an important part of this intimate role in patients' lives.11 Understanding the common factors influencing contraceptive use is important for nurses in this role.
Special Populations
Adolescents
Adolescents, defined as ages 10-19, are in a transitional period between childhood and adulthood.12 In the U.S., it is estimated that by age 15, 21% of young females have had intercourse.13 This vulnerable population struggles with the following barriers and influences when seeking contraceptives.14 Inconvenient medical clinic hours since they are in school, and clinic hours are typically not available after hours.14 Studies have found that many adolescents were concerned about the cost of contraception.14,15 Additionally, many adolescents fear the lack of confidentiality when seeking contraceptive treatment. This has been found to be higher among adolescents covered by their parents’ private insurance than among those covered by Medicaid. Adolescents with a college-educated mother have been found to be more concerned about confidentiality than those with mothers who have a high school diploma.14,16
In many cases, the healthcare providers themselves may act as a barrier by imposing their personal values or moralistic beliefs on the adolescent.14 These beliefs or values can be forced onto adolescents by delaying the initiation of contraception to rule out pregnancy.17 This can result in unwanted pregnancies when sexually active women wait for their next menses or employ a prolonged period of abstinence before initiating hormonal contraception.17 Additionally, healthcare providers may use an adolescent’s chronic health condition inappropriately as a medical contraindication for contraceptive use.14 Nurses can help this vulnerable population address these barriers by providing evidence-based information and emotional support.7
Postpartum
The postpartum period covers the 12 weeks following delivery, but can extend up to 12 months after a woman gives birth.18,19 Due to the risk involved for the mother and fetus if another pregnancy happens too soon, contraceptive conversations are essential. There are four main factors that impact a mother’s decision to use contraceptives during this period. Women consider parity, the number of pregnancies they have that reach 20 weeks or beyond, as a factor in their decisions.20,21 In addition, a higher level of education increases the likelihood that a mother will use an IUD or more long-term permanent birth control.20 Additionally, financial barriers are a concern for this population as well.22
Mothers in the postpartum period need additional support during this highly vulnerable time. Nurses can assist mothers with providing patient-centered information and emotional assistance.
Norgestrel: Nonprescription Daily Oral Contraceptive
On July 13, 2023, norgestrel was approved by the Federal Drug Administration in the United States as the first nonprescription daily oral contraceptive.23 Norgestrel is a progestin-only contraceptive that suppresses ovulation, thickens the cervical mucus to inhibit sperm penetration, and lowers the mid-cycle luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In addition, it slows the movement of the ovum through the fallopian tubes and alters the endometrium.24
Common Concerns
Will the use of norgestrel worsen the clinical course for individuals with progestin-sensitive cancers or increase the risk of recurrence?12 A contraindication for the drug is known or suspected progestin-sensitive cancer or carcinoma of the breast. Patients with these factors should NOT take this drug.24
Patients have a high frequency of vaginal bleeding on this drug. When should a patient seek medical treatment?12 Although the risk of vaginal bleeding being associated with a serious condition is low, nurses should encourage patients to seek medical treatment for further evaluation.24
Will taking norgestrel reduce bone mineral density?12 At this time, the prescription labeling for progestin-only oral contraceptives does not recommend monitoring of bone mineral density.24
Nonpharmacologic Therapies
Fertility Awareness Methods
Fertility-awareness methods center on a couple avoiding sexual intercourse during times of the menstrual cycle when conception may occur.27 There are many available methods that fall under the term fertility-based methods, each with varying levels of effectiveness and user-friendliness.27 These methods include the use of physiological data, such as basal body temperature and cervical mucus changes, to determine a fertility window.27 While perfect adherence to these methods can lead to effectiveness, they require a strong understanding and commitment from both partners.27
Barrier Techniques
As with fertility-based methods, the success of barrier techniques depends on a patient’s ability to use them consistently and correctly.4 Because of this, they are associated with higher failure rates than other methods.4 Barrier techniques include the use of male condoms, which are also called rubbers, sheaths, prophylactics, and skins.28 Male condoms work by preventing semen from directly contacting the vagina.4 Condoms can be made from either latex, polyurethane, or lamb cecum and (aside from lamb cecum condoms) have the added benefit of preventing sexually transmitted infections (STIs) and sexually transmitted diseases (STDs).28 Latex condoms are available in numerous sizes, shapes, and thicknesses.28 Latex condoms should only be used with water-based lubricants, because oil-based formulations can degrade these condoms, making them less effective.4,28 Polyurethane condoms do not have this risk.7 Internal (female) condoms are available as well. These are polyurethane sheaths with a flexible ring at the bone ends.4 Internal condoms have higher failure rates than external condoms and should never be used in conjunction with external condoms.4 Patients should be counseled on the correct use of condoms, which includes placing the condom correctly and avoiding the reuse of a condom. Other barrier methods include diaphragms and cervical caps.
Spermicides
Spermicides are chemical surfactants (surface-active agents) that kill sperm by destroying their cell walls and preventing sperm from entering the cervix.4,28 They are available in many formulations, including creams, films, foams, gels, suppositories, sponges, and tablets.28 Over-the-counter spermicides contain an agent called nonoxynol-9.28 A prescription spermicide is also available that contains lactic acid, citric acid, and potassium bitartrate.4 It works by lowering pH and reducing sperm motility.1 Spermicides differ in their method of application, onset, and duration of action, and healthcare professionals should counsel patients on appropriate use.28
Nonhormonal Contraceptive Intravaginal Gel
Phexxi® is an intravaginal, nonhormonal gel that provides a new barrier method option for patients.2,29 It includes lactic acid 1.8%, citric acid 1%, and potassium bitartrate 0.4%.2,29 Patients should be counseled to insert the gel within 1 hour before intercourse.2,29 By maintaining the acidic environment of the vagina, it is able to inhibit sperm motility while also acting as a barrier to sperm at the cervix via its viscous texture.2,29 In terms of typical use, intravaginal gel was shown to have an efficacy rate of 86.3% in the AMPOWER study.2 Common side effects include vaginal burning (18% of users) and itching (14.5% of users).29 Patients may possibly experience cystitis and urinary tract infections as well.2,29
Phexxi may benefit patients who desire a nonhormonal birth control option but do not wish to utilize the copper (nonhormonal) intrauterine device, those who prefer an on-demand option, and those who have allergies or do not wish to use condoms.2 The gel is also a reasonable option for women who are postpartum or breastfeeding, those who need a short-term alternative birth control method, and those approaching menopause.2 It should be noted that this is not preferred for women who desire a highly efficacious form of birth control.2
Hormonal Contraception
Hormonal contraceptives are comprised of estrogen and progestin or a progestin alone.4 This type of birth control is available in many formulations, including oral contraceptives, transdermal patches, vaginal rings, long-acting injections, subdermal implants, and intrauterine devices (IUD).4
Combined Hormonal Contraceptives
Combined hormonal contraceptives (CHCs) work to prevent conception before fertilization occurs by inhibiting the hypothalamic-pituitary axis.4,5 CHCs contain both progestin and estrogen.4,27 Progestins are synthetic forms of progesterone, and many types are available, differing in their estrogenic, antiestrogenic, and androgenic effects.4 Progestins thicken cervical mucus, which prevents sperm penetration, delays sperm transport, and causes atrophy of the endometrium.4,5 Progestins also suppress ovulation by lowering LH levels.4,5 Estrogens suppress FSH release, preventing dominant follicle development, and play an important role in providing cycle control.4,5 Synthetic estrogens used within CHCs include ethinyl estradiol (EE). EE is the most utilized estrogen, with doses ranging from less than 20 mcg to 50 mcg.4 EE has a long half-life, which lends to its efficacy and effects on bleeding control.2 Some women may be intolerant to EE, and fortunately, there are other estrogens available, including estradiol valerate and estetrol.2 Esterol is a novel estrogen included in the product Nexstellis.2 Research has found it causes minimal impact on the synthesis of coagulation factors and hepatic metabolism, and studies have shown a decreased incidence of venous thromboembolism when compared to traditional COCs.2 Newer estrogens have demonstrated similar side effects as their traditional counterparts.2
Combined hormonal contraceptives are available in various forms, including oral pills, vaginal rings, and transdermal patches.5 They are moderately effective at preventing pregnancy.5
Combined Oral Contraceptives (COC)
Combined oral contraceptives are available in monophasic and multiphasic forms. Monophasic COCs contain equivalent amounts of estrogen and progestin and are taken for 21 days.4 The following seven days include a set of placebo pills.4 Multiphasic forms can be biphasic, triphasic, or quadriphasic, with varying amounts of estrogen and progestin.4 They also follow a 21-day estrogen and progestin phase, followed by seven days of placebo pills.4 Natazia is an available quadriphasic regimen that includes estradiol valerate and dienogest as the progestin.2,30 It has been used to treat heavy menstrual bleeding.2,30 Data have not demonstrated a significant difference in either safety or efficacy between multiphasic and monophasic tablets.4 COCs can also be taken in an extended-use fashion.4 In these cases, the active tablets are taken continuously for at least 84 days, and this is followed by seven days of inactive pills or pills that only contain estrogen.4
The choice of COC will depend on the hormonal content, dose, preferred formulation, and any existing medical conditions the patient may have.4 In general, a COC that has 35 mcg or less than EE is recommended, as it may be associated with less risk of thromboembolism, stroke, or myocardial infarction (MI).4 However, women may be at a greater risk of pregnancy when using COCs that contain less than 35 mcg of EE.4 Compared to progestin-only contraceptives, COCs generally produce a more regular and consistent pattern of bleeding for patients.1
Initiating Combined Oral Contraceptives
Patients may choose from several methods when starting a COC regimen. These include taking the first pill on the first day of their menstrual cycle, taking the first pill on the first Sunday after their menstrual cycle begins, or using a quick start method (starting the day they receive the pills).4 When using the quick start method, the menstrual period will be delayed until the active tablets have been completed within the pack.4 Women should use a second method of contraception (such as condoms) or avoid sexual intercourse for a minimum of seven days after starting any oral contraceptive.4
Side Effects of Combined Oral Contraceptives
Common side effects associated with COC include nausea, bloating, and breakthrough bleeding.4 These tend to improve over time as hormone levels adjust.4 Due to these hormonal changes, it is generally recommended not to switch formulations before a COC has been used for at least 2-3 months.4 Irregular bleeding can also occur with the use of COCs, and this commonly occurs during the first six months of therapy.1,4 The acronym ACHES is used to remember serious side effects of COCs that should be immediately discussed with a provider and will likely result in discontinuation of COCs.4 These side effects include abdominal pain, chest pain, headaches, eye problems, and severe leg pain.4
Clinicians should be diligent in assessing potential drug-drug interactions with COCs. In general, women should be counseled to use a second form of birth control if there is a possibility of a drug interaction with their COC. Rifampin can decrease the effectiveness of birth control.31 Other antibiotics may as well, but these interactions are not as well-documented.4 Women taking anticonvulsant medications such as phenobarbital, carbamazepine, or phenytoin should utilize a form of birth control other than COC.4 These anticonvulsants can metabolize estrogen and progestin, which reduces COC efficacy.4 Other potential drug interactions involve antiretroviral medications, which can decrease the effectiveness of COC; medications that increase potassium, which could result in hyperkalemia in women taking drospirenone; and St. John’s Wort, which may decrease COC effectiveness.4 In general, all of a patient’s medications should be reviewed to ensure no drug-drug interactions will affect the safety and efficacy of contraceptive therapy.
Counseling Patients on Combined Oral Contraceptives
Patients should be counseled on what to do if they miss one or more doses of their COC. If a patient misses one dose of their medication, they should be told to take the missed dose as soon as they remember and then resume the remainder of the dose schedule as prescribed.4 If two or more doses are missed, they should take one of the missed tablets and discard the rest.4 In this case, they should also use a second form of contraception until the active hormone tablets have been taken for at least seven days. They may also require counseling on the use of emergency contraception.
Transdermal Contraceptives
Two transdermal patches are available for use: Xulane®, which contains 0.75 mg of EE and 6 mg of norelgestromin, and Twirla®, which contains 30 mcg of EE and 120 mcg of levonorgestrel.32,33 To date, there is no head-to-head comparison of these two patches.2 Twirla offers the benefit of lower doses of hormones, lower detachment rates, and less site irritation compared to Xulane.2 Twirla users also experienced less nausea, headaches, and fatigue compared to COC users.2 The norelgestromin patch tends to cause less breakthrough bleeding and spotting compared to COC by cycle 13.2
In patients who weigh less than 90 kg, the patch is as effective as oral contraceptives.4 It is not recommended to be used first-line in patients weighing more than 90 kg, given the results of comparative trials.33 The patch can be applied to either the abdomen, buttocks, upper torso, or upper arm at the start of a menstrual cycle, and it is removed and replaced weekly for 3 weeks.32 The fourth week of the cycle is patch-free.32 Once the patch is applied, steady-state levels are reached within 48 hours and then maintained until the patch is removed.2
Patients should be counseled only to wear one patch at a time.32 If the patch is removed for less than 24 hours (for any reason), it can be replaced (or a new patch used), and no secondary birth control method is needed.32 If it is removed for more than 24 hours, a new patch should be applied, and a secondary form of contraception should be used for at least 7 days.32 If the patch is removed during the third patch week, the hormone-free week should be skipped, and a new patch should be applied instead.32
Side effects of the transdermal patch include application-site reactions (erythema, irritation) and effects like those of oral contraceptives, including headache and nausea.32,33 The patch does contain 60% more estrogen than oral contraceptives, and thus may place patients at greater risk of thromboembolic events.32 The patch may benefit patients who have trouble with adherence, and the higher estrogen dose in norelgestromin can benefit those with acne.2 Women at higher risk of VTE should not use the patch.2
Vaginal Rings
Various vaginal rings are available for use, including NuvaRing, EluRyng, and Annovera.34-36 NuvaRing® and EluRyng® contain both EE and etonogestrel, while Annovera contains segesterone acetate and ethinyl estradiol.34-36 Nuvaring and EluRyng are placed for three weeks at a time, during which they release 15 mcg of EE per day and 120 mcg of etonogestrel per day.34-36 The ring is inserted on or before day 5 of the menstrual cycle.4 It is kept in place for 3 weeks, then removed for 1 week to allow for bleeding.34,35 The exact placement of the ring is not an issue because hormones are able to be absorbed anywhere in the vagina.34,35 There is also no risk of inserting the ring too far, as the cervix will block it.34,35
Rings should never be flushed down the toilet; instead, they should be placed in the foil patch and discarded in the trash.4 If either the NuvaRing or EluRyng is displaced for less than 3 hours, a new ring can be placed with no secondary form of birth control required.4 However, if it has been displaced for three or more hours, a new ring should be placed, and a secondary form of birth control should be used for at least seven consecutive days.4 If the ring should become displaced during the third week of use, a new ring should be placed and kept in place for 21 days.4 It is recommended to rinse the ring in lukewarm water prior to reinsertion.34,35
Annovera® is a 13-cycle combined vaginal ring that offers patients a year of birth control while using the same ring.36 It is placed for 21 days and then removed for 7 days to allow for menses.36 The effectiveness of Annovera has been shown to be 97.3% when used as recommended.2 Expulsion of Annovera is more likely in the first cycle, and patients do not require a backup contraceptive method if the ring is reinserted within 2 hours.2
The side effects and warnings associated with vaginal ring use are like those associated with oral contraceptives. Cigarette smoking increases the risk of serious side effects from estrogen and progestin vaginal ring, including heart attacks, blood clots, and strokes.35,36 Patients may discontinue use due to vaginal symptoms or device expulsion.4 However, many patients experience better cycle control with the vaginal ring compared to the use of oral contraceptives.4 In general, patients do not find the use of the ring to be uncomfortable.4 Vaginal rings may not be preferred by patients who find rings painful or uncomfortable, those with arthritis in the hands, those with pelvic floor dysfunction, and those with other conditions that may limit the correct placement and use of vaginal rings.2 The ring is beneficial for patients seeking a reversible, longer-acting method that is not an injection and does not require the daily adherence of an oral method.2
Important Considerations of CHC Use
Armed with knowledge of the benefits and risks of CHCs, the healthcare team can collaborate to assist their patient in making informed decisions regarding contraceptive therapy. The chosen form of CHC must be appropriate for the patient based on their medical history, lifestyle, ability to adhere to therapy, and therapy goals.1,4 Per the American College of Obstetricians and Gynecologists (ACOG), clinicians should complete a thorough medical history and obtain a blood pressure reading before prescribing oral contraceptives.37-39 A discussion of the goals of therapy and the risks and benefits should be held with the patient before determining the best choice of CHC. Combined oral contraceptives can provide patients with numerous non-contraceptive benefits, such as reduced menstrual cramps, improved menstrual regularity, improved acne, and reduced iron-deficiency anemia.4 Patients may prefer a certain type of CHC to assist with these benefits as well.
Patients should be counseled that CHCs do not protect against STDs and STIs, and patients should be counseled on the appropriate use of condoms to prevent these conditions.4 The following is a list of absolute and relative contraindications to the use of oral contraceptives that should be reviewed by the healthcare team.2
Women Older than 35 Years of Age: Women can remain fertile into their 40s; the use of contraception is important in this cohort. The benefit of using oral contraceptives should be weighed against potential risks, which can include an increased risk of VTE in perimenopausal women older than 40.4 When low-dose formulations are used in healthy, non-obese women older than 40, there is not a significant risk of cardiovascular disease.4 If women older than 35 years of age have migraine disorders with aura, uncontrolled hypertension, smoke, or have diabetes with vascular disease, they should not be prescribed CHCs.38
Smoking: Women older than 35 years of age who smoke and use CHCs may have an increased risk of MI or stroke.4 Women who meet these criteria should only be prescribed CHCs cautiously, and other methods of birth control should be explored. If women smoke more than 15 cigarettes a day, CHC use is contraindicated.38 These women should consider the use of progestin-only or non-hormonal contraceptive options.4
Hypertension: CHC use can lead to small increases in blood pressure, regardless of the dose of estrogen prescribed.4 Some studies have demonstrated an increased risk of MI and stroke in patients with hypertension who use CHCs.4 Low-dose CHCs may be considered in women less than 35 years of age who have well-controlled blood pressure. If a woman has uncontrolled hypertension, with a systolic blood pressure greater than 160 mmHg or a diastolic blood pressure greater than 100 mmHg, CHCs should be avoided, and alternative methods sought.4
Dyslipidemia: Progestins may decrease high-density lipoprotein (HDL) levels and increase low-density lipoprotein (LDL) levels.4 Conversely, estrogens may benefit patients by increasing the removal of HDL and increasing HDL levels.4 Overall, low-dose CHCs will not significantly impact lipid levels and, thus, women with dyslipidemia as a single risk factor can use CHCs.2 However, if they have multiple cardiovascular risk factors, alternative methods of contraception should be sought.4
Diabetes: Low-dose CHCs should not significantly impact women with diabetes in terms of either glucose or hemoglobin A1c levels.4 If a patient has diabetes and vascular disease, or has had diabetes for more than 20 years, they should not use CHCs.4
Migraine Headaches: CHC use has been shown to increase and decrease the frequency with which women with migraines experience these types of headaches.4,39 Women who have migraines with aura may be at an increased risk of stroke if they use CHCs.4 CHCs can be used in women with migraines without aura who are otherwise healthy.4 Women with migraines with aura should not use CHCs regardless of age and should consider other contraceptive methods or a progestin-only oral contraceptives.4,40
Breast Cancer: Women who use CHCs may be at a slightly increased risk of developing breast cancer compared to those who never used hormonal contraception.37 This risk is greater the longer CHCs are used and in women older than forty.2 The risk of breast cancer returns to levels of non-CHC users once CHC use is discontinued.2 Women older than 40 or those with an increased risk of breast cancer should not use CHCs.2
Thromboembolism: Women who use CHCs are at a threefold higher risk for thromboembolic events than those who do not.4 This includes deep vein thrombosis (DVT) or pulmonary embolism (PE). The underlying mechanism is increased hepatic production of Factor VII, Factor X, and fibrinogen within the coagulation cascade via estrogen.4 New progestins used in oral contraceptives (such as norgestimate and drospirenone) may incur a higher risk.4 Product labeling for transdermal patches and products containing drospirenone now includes a warning about the risk of thromboembolism.41 Women with an increased baseline risk of thromboembolism should consider CHCs that contain either older progestins or other non-hormonal forms of birth control.4
Obesity: Obese women may be at an increased risk of birth control failure; however, the risk of CHCs and non-hormonal birth control failing is low.4,38 Additionally, use of progestin-only contraceptives is safe in obese women.4
Progestin-Only Contraceptives
Progestin-only contraceptives, as the name implies, contain progestin without estrogen.5 These contraceptives are available as pills, implants, injections, and intrauterine devices (IUDs).
Progestin-Only Pills (POPs)
Progestin-only pills contain either norethindrone or drospirenone.1,5 Norethindrone is dosed at 0.35 mg daily and drospirenone at 4 mg daily.2 Drospirenone is a spironolactone derivative and has antiandrogenic properties; therefore, it may benefit patients through its effects on acne and fluid retention.2,42 Progestin-only pills work by inhibiting ovulation in 50-70% of user cycles and can prevent pregnancy through mechanisms that impact cervical mucus.2 Patients can use POPs to bridge other forms of birth control (such as one requiring a future procedure).2 Benefits of use include quick return of fertility following cessation of therapy, minimal side effects, and safety for patients who may have contraindications to CHCs.4,5 Use of progestin-only pills requires strict adherence from patients. These pills are taken on a continual basis, with no interval of hormone-free pills.5 Missing a progestin-only oral contraceptive is different from missing a combined hormonal oral contraceptive. Norethindrone pills have a shorter half-life than CHC pills, and if a woman is only three hours late in taking the progestin-only tablet, a second form of birth control should be used for at least 48 hours.4,5
Common side effects of POP include either prolonged or unscheduled bleeding that is more likely to occur during the first six months of therapy.2 Patients may eventually notice lighter or absent periods over time.2 Clinicians should counsel patients on what to expect in terms of bleeding patterns during the first year of use to improve adherence rates.2 In a study that included 700 participants, drospirenone was not found to increase the incidence of cardiovascular events or hyperkalemia.43
Injectable Progestin
Injectable progestin provides a long-term contraceptive option for women. This medication is injected into the skin and releases sustained levels of progestin that can inhibit ovulation.4,44 This option may be beneficial for women who are breastfeeding, estrogen-intolerant, or women who have a medical history that precludes the use of estrogens.4 This form of birth control also offers increased adherence, with lower failure rates than CHCs.4
Depo-Provera (depot-medroxyprogesterone acetate (DMPA)) is an injectable progestin that is given via injection every 3 months either in the gluteal or deltoid muscle (intramuscular, IM) or in the abdomen or thigh (subcutaneous, SubQ).44 It is injected within five days of the first day of bleeding.43 Depo-Provera comes as a 150 mg/mL injection vial and is also available as a prefilled syringe for IM injections.44 Depo-SubQ Provera is also available as a prefilled syringe. These forms are traditionally administered in a medical office or clinic, but the Centers for Disease Control and Prevention has recommended the 104 mg SC DMPA, which can be self-administered at home.44 The ability to self-administer DMPA has led to increased adherence and higher rates of continuation. In one study, 97% of patients reported that DMPA was easy to administer, and the satisfaction rate was 87%.2 It is important that patients receive counseling on the appropriate administration and disposal of sharps.2
If DMPA is administered at any time after day 7 of a cycle, a secondary form of contraception is needed for seven days.4 A confirmation that the patient is not pregnant is required prior to administration.4,44 Contraindications for use include a current diagnosis or history of breast cancer, thromboembolic disorders, cerebral vascular disease, or significant hepatic disease.44 Depo-Provera is the only form of birth control that can delay a return to fertility.1 Thus, it is not a first-line option for women who want to become pregnant soon, as its effects can persist for up to 12 months following the final dose.1,4
Side effects include menstrual irregularities such as spotting and amenorrhea that may occur throughout the first year.4,44 The incidence of amenorrhea among women who use DMPA may be as high as 68% after 2 years.4 Other side effects include weight gain and breast tenderness.44 Some longitudinal studies have found effects on bone mineral density, and DMPA has a black box warning that it should not be continued for more than 2 years unless other means of contraception are inadequate. Bone density loss may not be reversible.44
Long-Acting Reversible Contraception (LARC)
Long-acting reversible contraception includes IUDs and implants that may be hormonal or non-hormonal. The benefit of LARC is its high efficacy, but it also allows for a quick reversal of fertility once it is removed.4 Like the injection, they have excellent efficacy rates, and adherence is not an issue as it is with CHCs.4 Nexplanon is an implant (small, polymer rod) that contains 68 mg of etonogestrel, which is released at a rate of 60 mcg daily for the first month of use and then 30 mcg daily until the end of three years.5,44 Some data suggest it can be used for up to 5 years, with efficacy rates higher at five years out than those of DMPA, pills, rings, or patches.2 Clinicians should discuss the options of keeping the implant in place for up to five years with their patients.2 Risks include the potential for irregular bleeding, and the extended-use method may not be efficacious in patients with a BMI >/30 kg/m2.2
The implant is placed under the skin of the nondominant upper arm.43 Clinicians should ensure patients are not pregnant prior to insertion and need to be trained on proper insertion methods.4 Ideally, the implant should be inserted between Day 1 and Day 5 of a cycle; if not, the woman should use a backup method of birth control for 7 days.4 Fertility should return within 30 days of implant removal.4
The implant is associated with irregular menstrual bleeding, which is a major counseling point to ensure women are comfortable with the use of the implant.45 It also may cause weight gain and patients to become emotionally labile.5 Nexplanon may interact with CYP450 inducers, such as rifampin and phenytoin.24 Contraindications include progestin-sensitive cancer, thrombosis, and undiagnosed abnormal bleeding.45
Another form of LARC is IUDs. To date, there are five types of IUDs available, including four hormonal versions that contain levonorgestrel (Mirena®, Skyla®, Liletta®, and Kyleena®) and one non-hormonal version made with copper (Paragard®).46-50 IUDs exert their contraceptive effects through various mechanisms, including inhibition of sperm migration, disrupting ovum transport, and damaging a fertilized ovum.4 The hormonal versions may also thicken cervical mucus and cause endometrial suppression.4 Paragard can be left in place for up to 10 (and potentially 12) years; it may be associated with heavier periods and possible dysmenorrhea.46 Mirena can be left in place for 8 years, Kyleena for up to 5 years, Liletta for up to 8 years, and Skyla for up to 3 years.47-50 IUDs can be inserted on any day of the menstrual cycle. If it is not inserted between days 1 and 7, a backup method will be needed for 7 days.1 Insertion can be painful for patients, and counseling them to take an NSAID or acetaminophen prior to insertion may be helpful.4 Similar to the implant, the longer IUDs are kept in place, the more bleeding patterns may be impacted.4
Common side effects associated with the use of IUDs include irregular menstrual bleeding.44-48 Patients may also experience amenorrhea (absence of menses) when using the hormonal versions.5 Contraindications to use include pregnancy, pelvic inflammatory disease, presence of an STI or STD, post-abortion sepsis, purulent cervicitis, undiagnosed vaginal bleeding, uterine anomaly, allergy to an IUD component, or Wilson’s disease for the copper IUD. 46-50
Selecting a Contraceptive Method
Table 2 presents reasons for patients and clinicians to consider various contraceptive methods.
Table 2
Benefits of Contraceptive Methods for Suggested Patient Populations
| Method of Birth Control | Consider for Patients a Method that: |
| Condoms | Provides STI protection Is reversible Is short-acting Is breastfeeding compatible Is a nonhormonal method Does not involve injections |
| Spermicide | Is reversible Is short-acting Is breastfeeding compatible Is a nonhormonal method Does not involve injections |
| Nonhormonal intravaginal gel | Is reversible Is short-acting Is breastfeeding compatible Is a nonhormonal method Does not involve injections |
| Combined oral contraceptives | Is reversible Does not involve injections Provides acne benefits Provides cycle stability |
| Progestin-only pills | Is reversible Is short-acting Is breastfeeding compatible Does not involve injections Is safe if estrogen-intolerant Is safe for those with VTE risk factors |
| Transdermal patch | Is reversible Is short-acting Does not involve injections Will increase adherence |
| Vaginal ring | Is reversible Is short-acting Does not involve injections Will increase adherence |
| Implant | Is reversible Is long-acting Does not involve injections Will increase adherence |
| IUD | Is reversible Is long-acting Does not involve injection Will increase adherence Is non-hormonal (copper IUD only) |
Counseling Patients on Contraception
All members of the healthcare team, including physicians, pharmacists, and nurses, should work together collaboratively with the patient to 1) identify the patient’s goals related to family planning and reproductive outcomes, 2) assist the patient in making informed decisions, and 3) optimize health outcomes for the patient.3 This shared decision-making process involves the patient sharing their preferences, and the medical team offering suggested methods that align with those preferences.3 The following steps, set out in Table 3, can be utilized to provide patient-centered contraceptive counseling.3 At each step, members of the health care team can work inter-professionally, utilizing their specific skill sets to ensure the patient receives and is counseled on a preferred, safe, and effective contraceptive method.3
Table 3
Steps in the Contraceptive Counseling Process3
| Steps | Description |
| Establish a positive, interpersonal relationship with the patient to optimize patient comfort |
| Identify patients who are appropriate for contraceptive counseling by asking if they wish to discuss contraception or pregnancy prevention |
| Assess for common medical conditions that are contraindications to contraceptive methods (smoking status, history of VTE) |
| Determine patient preferences by involving them in a shared decision-making process |
| Help patient identify preferences by having them consider the following characteristics of contraceptives (how often they are taken, efficacy, effect on menstrual bleeding (including regularity and flow, non-contraceptive benefits, effect on future fertility) |
| Counsel on how to start using the contraceptive method, what to do if a dose is missed, and how to identify serious side effects |
Interprofessional Collaboration
Physicians may not be aware that their patient is using a nonprescription contraception and may have to rely on the interprofessional team to ensure patient safety and effective contraception. Nurses may guide patients, friends, and family members through this new experience of purchasing birth control without a physician’s prescription. Pharmacists often conduct patient assessments, including reviewing the patient's medical history and any contraindications. They may ask about smoking habits, blood pressure, and other relevant factors to ensure the chosen contraceptive is safe and appropriate for the individual.25,26 This assessment involves the following:25,26
Whether the patient ever had breast cancer.
Whether the patient is already pregnant or suspected of being pregnant
Whether the patient is currently taking another form of hormonal birth control (e.g., a patch, injection, or IUD)
Below are a few of the main concerns and contraindications. For a full review, please go to the FDA website.
Patient Case
Maria G., a 28-year-old female, presents to the clinic for contraception due to irregular menses and heavy menstrual bleeding impacting her work. What questions can be asked of the patient?
She is a healthy nonsmoker, with a BMI of 24 kg/m2 and no comorbidities. She is sexually active with her husband and desires a low-maintenance, reversible method with minimal side effects. She expresses anxiety about weight gain and mood changes from prior use of COCs. She shares that she does not want to become pregnant due to her career goals. What are the next steps for treatment options for this patient?
Shared decision-making resulted in her decision to initiate levonorgestrel IUD as a long-acting reversible contraceptive with typical use failure of <1%. She is not menstruating this week, so was counseled to return for insertion within the first 7 days of the next menses. She was counseled that no backup contraceptive is needed. She was advised about the procedure, possible discomfort and pain management, and to monitor for irregular bleeding. Additional instructions include following up in 4 to 6 weeks after the procedure to check for proper placement and to monitor for complications.
Emergency Contraception
Emergency contraception (EC) is used to prevent an unintended pregnancy following unprotected or inadequately protected sex, such as when no contraception is used, a condom breaks, or a sexual assault occurs.4 Physicians may also choose to provide patients with an advanced prescription of EC when they use contraceptive methods with higher failure rates (such as the intravaginal gel).2 Options for EC include progestin-only (levonorgestrel) and progesterone receptor modulator (ulipristal) products.4 The Paragard IUD can also be inserted, or a high dose of an oral contraceptive can be utilized.4 The mechanism of EC is via inhibiting or delaying ovulation.2 The levonorgestrel formulation should be taken within 72 hours of unprotected sex, and the earlier this is taken, the better the efficacy.52 It may be effective up to 5 days later.52 A second form, ulipristal acetate, delays ovulation.52 This EC must be taken within 5 days of unprotected intercourse.52 The overall effectiveness of EC has been found to range from 59% to 94%.2 Women who use EC may experience nausea, vomiting, and/or irregular bleeding.4
Summary
Choice of contraception should involve the clinician and patient using a shared decision-making model, given the personalized nature of each patient with respect to goals, past medical history, and preferences. It is essential that every patient receive a safe, effective, and preferred choice of contraceptive agent, especially given that adherence correlates with patient satisfaction. Considerations for selection are numerous and include effectiveness, adherence, side effects, safety, time to return to fertility, and preferred method. Healthcare professionals should spend sufficient time counseling patients on side effects, ways to mitigate side effects, serious side effects that require medical attention, and proper methods of contraceptive use.
References
Teal S, Edelman A. Contraception Selection, Effectiveness, and Adverse Effects: A Review. JAMA. 2021;326(24):2507-2518. doi:10.1001/jama.2021.21392
Fiffick A et al. Update on current contraceptive options: A case-based discussion of efficacy, eligibility, and use. CCJM. 2023;90(3)181-190.
Dehlendorf C, Grumbach K, Schmittdiel JA, Steinauer J. Shared decision making in contraceptive counseling. Contraception. 2017;95(5):452-455. doi:10.1016/j.contraception.2016.12.010
El-Ibiary SY, Shrader SP, Ragucci KR. Contraception. In: DiPiro JT, Yee GC, Posey L, Haines ST, Nolin TD, Ellingrod V. eds. Pharmacotherapy: A Pathophysiologic Approach, 11e. McGraw Hill; 2020.
Britton LE, Alspaugh A, Greene MZ, McLemore MR. An Evidence-Based Update on Contraception. Am J Nurs. 2020;120(2):22-33.
World Health Organization. Medical eligibility criteria for contraceptive use, 6th ed. Executive Summary. WHO. November 3, 2025. Accessed April 23, 2026. https://iris.who.int/server/api/core/bitstreams/c8aaef2d-6916-4f98-92cb-cfabcc0782e3/content
Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1-126. Published 2024 Aug 8. doi:10.15585/mmwr.rr7304a1
Lesinskienė S, Andruškevič J, Butvilaitė A. Adolescent Pregnancies and Perinatal Mental Health-Needs and Complex Support Options: A Literature Review. J Clin Med. 2025;14(7):2334. Published 2025 Mar 28. doi:10.3390/jcm14072334
The American College of Obstetricians and Gynecologists. Interpregnancy Care. www.acog.org. Published 2021. Accessed April 23, 2026. https://www.acog.org/clinical/clinical-guidance/obstetric-care-consensus/articles/2019/01/interpregnancy-care
McConnell A. Rural Georgia gets more contraceptive options through expanded delivery of birth control implants. Georgia Recorder. Published August 13, 2023. Accessed April 23, 2026. https://georgiarecorder.com/2023/08/13/rural-georgia-gets-more-contraceptive-options-through-expanded-delivery-of-birth-control-implants/
Parker EC, Kong K, Watts LA, Schwarz EB, Darney PD, Thiel de Bocanegra H. Visits to Registered Nurses: An Opportunity to Increase Contraceptive Access in California. Nurs Res. 2017;66(4):286-294. doi:10.1097/NNR.0000000000000229
Minerve Murry K. Decisional Memorandum New Drug Application 17031 Supplement 41 Application for Full Prescription-to-Nonprescription Switch of Norgestrel Tablets 0.075 mg. United States Food and Drug Administration. Published July 10, 2023. Accessed April 23, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/017031Orig1s041SumR.pdf
Centers for Disease Control and Prevention. Sexual Activity and Contraceptive Use Among Teenagers Aged 15–19 in the United States, 2015–2017. CDC. Published May 2020. Accessed April 23, 2026. https://www.cdc.gov/nchs/products/databriefs/db366.htm#:~:text=By%20age%2015%2C%2021%25%20of,had%20ever%20had%20sexual%20intercourse
Todd N, Black A. Contraception for Adolescents. J Clin Res Pediatr Endocrinol. 2020;12(Suppl 1):28-40. doi:10.4274/jcrpe.galenos.2019.2019.S0003
Yarger J, Schroeder R, Blum M, et al. Concerns About the Cost of Contraception Among Young Women Attending Community College. Womens Health Issues. 2021;31(5):420-425. doi:10.1016/j.whi.2021.03.006
Fuentes L, Ingerick M, Jones R, Lindberg L. Adolescents' and Young Adults' Reports of Barriers to Confidential Health Care and Receipt of Contraceptive Services. J Adolesc Health. 2018;62(1):36-43. doi:10.1016/j.jadohealth.2017.10.011
Leeman L. Medical barriers to effective contraception. Obstet Gynecol Clin North Am. 2007;34(1):19-vii. doi:10.1016/j.ogc.2007.01.003
Paladine HL, Blenning CE, Strangas Y. Postpartum Care: An Approach to the Fourth Trimester. Am Fam Physician. 2019;100(8):485-491.
Parham L, Clarke R, Ornelas M, Li S, Guendelman S. Opportunities and Challenges to Improve Postpartum Care: Payors' and Purchasers' Perspectives in California. Womens Health Rep (New Rochelle). 2025;6(1):464-475. Published 2025 Apr 21. doi:10.1089/whr.2024.0198
Robinet L, Jeffredo A, Clesse C. Factors Influencing Contraceptive Choice During the Postpartum Period: A Qualitative Systematic Review. J Midwifery Womens Health. 2023;68(2):265-286. doi:10.1111/jmwh.13471
The American College of Obstetricians and Gynecologists. reVITALize: Obstetrics Data Definitions. www.acog.org. Undated. Accessed April 23, 2026. https://www.acog.org/practice-management/health-it-and-clinical-informatics/revitalize-obstetrics-data-definitions#:~:text=by%20any%20clinician-
Potter JE, Hubert C, Stevenson AJ, et al. Barriers to Postpartum Contraception in Texas and Pregnancy Within 2 Years of Delivery. Obstet Gynecol. 2016;127(2):289-296. doi:10.1097/AOG.0000000000001201
Federal Drug Administration Commission. FDA Approves First Nonprescription Daily Oral Contraceptive. FDA. Published July 13, 2023. Accessed April 23, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-nonprescription-daily-oral-contraceptive
Federal Drug Administration. Opill® Tablets. FDA. 2017. Accessed April 23, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017031s035s036lbl.pdf
Sober S, Bradford R, Henrie B, et al. Evaluation of consumer self-selection of a proposed over-the-counter, progestin-only daily oral contraceptive. Contraception. 2024;133:110401. doi:10.1016/j.contraception.2024.110401
Federal Drug Administration. Opill (0.075mg Oral Norgestrel Tablet) Information. FDA. 01/16/2024. Accessed April 23, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/opill-0075mg-oral-norgestrel-tablet-information#:~:text=seek%20medical%20advice.-,Q.,If%20you%20are%20male
Simmons RG, Jennings V. Fertility awareness-based methods of family planning. Best Pract Res Clin Obstet Gynaecol. 2020;66:68-82.
El-Ibiary SY, Raney E. Prevention of Pregnancy and Sexually Transmitted Infections. In: Handbook of Nonprescription Drugs, 20e. APhA; 2020.
PHEXXI- lactic acid, l-, citric acid monohydrate, and potassium bitartrate gel. Prescribing Information. Evofem, Inc. Updated November 21, 2023. Accessed April 23, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=173ff411-7227-47b0-94dc-844e1ebaf14e
NATAZIA- estradiol valerate and estradiol valerate/dienogest kit. Prescribing Information. Bayer HealthCare Pharmaceuticals Inc. Updated June 26, 2024. Accessed April 23, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02c91fba-9c47-43ef-ac78-e82369798834
Anderson LA. Antibiotics and Birth Control Pill Interactions: Fact or Fallacy? Drugs.com. Last updated on June 30, 2025. Accessed April 23, 2026. https://www.drugs.com/article/antibiotics-and-birth-control.html
XULANE- norelgestromin and ethinyl estradiol patch. Prescribing Information. Mylan Pharmaceuticals Inc. Updated March 4, 2022. Accessed April 23, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7848550-086a-43d8-8ae5-047f4b9e4382
TWIRLA- levonorgestrel/ethinyl estradiol patch. Prescribing Information. Agile Therapeutics, Inc. Updated July 3, 2024. Accessed April 23, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bcaf8db0-1750-425d-b008-255b5e7a9cc6
NUVARING- etonogestrel and ethinyl estradiol insert, extended release. Prescribing Information. Advanz Pharma (US) Corp. Updated March 21, 2025. Accessed April 23, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19ef66d1-913f-49a8-a0a5-59b4e20322f5
ELURYNG- etonogestrel and ethinyl estradiol ring. Prescribing Information. Amneal Pharmaceuticals LLC. Updated January 15, 2025. Accessed April 23, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6c8512d-b258-4be5-8c2f-0f1893f198b9
ANNOVERA- segesterone acetate and ethinyl estradiol ring. Prescribing Information. Mayne Pharma. Updated April 23, 2025. Accessed April 23, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb18194f-2021-41fa-8bdf-31e0c0eb646b
ACOG Practice Bulletin No. 206: Use of Hormonal Contraception in Women With Coexisting Medical Conditions [published correction appears in Obstet Gynecol. 2019 Jun;133(6):1288]. Obstet Gynecol. 2019;133(2):e128-e150.
Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(No. RR-4):1–66.
Curtis KM, Tepper NK, Jatlaoui TC et al. U.S. Medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(No. RR-3):1–104.
MacGregor EA. Contraception and headache. Headache. 2013 Feb;53(2):247-76. doi: 10.1111/head.12035.
Bhupathiraju SN, Grodstein F, Stampfer MJ, et al. Exogenous hormone use: oral contraceptives, postmenopausal hormone therapy, and health outcomes in the Nurses’ health study. Am J Public Health. 2016;106(9):1631–1637.
DROSPIRENONE AND ETHINYL ESTRADIOL- drospirenone and ethinyl estradiol kit. Prescribing Information. Lupin Pharmaceuticals, Inc. Updated December 2, 2025. Accessed April 23, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8955f3b-afc9-4ef0-8946-9c97ab5b2e05
Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability. Contraception. 2015;92(5):439–444. doi:10.1016/j.contraception.2015.07.014
MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION- medroxyprogesterone acetate injection, suspension. Prescribing Information. Hikma Pharmaceuticals USA Inc. Updated January 8, 2025. Accessed April 23, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0476eac5-d96c-4910-aa86-1ddeeefefe50
NEXPLANON- etonogestrel implant. Prescribing Information. Organon LLC. Updated January 16, 2026. Accessed April 23, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487f8a62-e142-457c-97cc-2e398fde7594
PARAGARD T 380A- copper intrauterine device. Prescribing Information. CooperSurgical, Inc. Updated June 1, 2024. Accessed April 23, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c420b53-c95e-46af-aebd-73741be58391
MIRENA- levonorgestrel intrauterine device. Prescribing Information. Bayer HealthCare Pharmaceuticals Inc. Updated October 29, 2025. Accessed April 23, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dcbd6aa2-b3fa-479a-a676-56ea742962fc
LILETTA- levonorgestrel intrauterine device. Prescribing Information. Allergan, Inc. Updated June 29, 2023. Accessed April 23, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaf0eb2a-f88a-4f26-a445-0fd30176c326
SKYLA- levonorgestrel intrauterine device. Prescribing Information. Bayer HealthCare Pharmaceuticals Inc. Updated March 4, 2026. Accessed April 23, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f44ff35-e052-49cd-a1c2-0bfd87d49309
Stifani BM, Madden T, Micks E, Moayedi G, Tarleton J, Benson LS. Society of Family Planning Clinical Recommendations: Contraceptive Care in the Context of Pandemic Response. Contraception. 2022;113:1-12. doi:10.1016/j.contraception.2022.05.006
AMAZON BASIC CARE LEVONORGESTREL- levonorgestrel tablet. Prescribing Information. Amazon.com Services LLC. Updated April 4, 2025. Accessed April 23, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10ecae6f-386f-e199-e063-6294a90a680b
ELLA- ulipristal acetate tablet. Prescribing Information. HRA PHARMA AMERICA, INC. Updated January 7, 2026. Accessed April 23, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2bf93d23-cddd-4613-9066-5b5fa090404b
DISCLAIMER
The information provided in this course is general in nature, and it is designed solely to provide participants with continuing education credit(s). This course and materials are not meant to substitute for the independent, professional judgment of any participant regarding that participant’s professional practice, including but not limited to patient assessment, diagnosis, treatment, and/or health management. Medical and pharmacy practices, rules, and laws vary from state to state, and this course does not cover the laws of each state; therefore, participants must consult the laws of their state as they relate to their professional practice.
Healthcare professionals must consult their employer, healthcare facility, hospital, or other organization for guidelines, protocols, and procedures to follow. The information provided in this course does not replace those guidelines, protocols, and procedures, but is for academic purposes only, and this course’s limited purpose is for the completion of continuing education credits.
Participants are advised and acknowledge that information related to medications, their administration, dosing, contraindications, adverse reactions, interactions, warnings, precautions, or accepted uses is constantly changing. Any person taking this course understands that such a person must make an independent review of medication information before any patient assessment, diagnosis, treatment and/or health management. Any discussion of off-label use of any medication, device, or procedure is informational only, and such uses are not endorsed hereby.
Nothing contained in this course represents the opinions, views, judgments, or conclusions of RxCe.com LLC. RxCe.com LLC is not liable or responsible to any person for any inaccuracy, error, or omission with respect to this course or course material.
© RxCe.com LLC 2026: All rights reserved. No reproduction of all or part of any content herein is allowed without the prior, written permission of RxCe.com LLC.
RxCe.com
© RxCe.com LLC 2025: All rights reserved.